InnoCare Pharma (09969): Zurletrectinib Included in the 2026 National Reimbursement Drug List

date
16/11/2026
Zhitong Finance APP news, InnoCare Pharma (09969) announced that, according to the "National Drug Catalog for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance (2026)" (Medical Insurance Issuance [2026] No. 29) (hereinafter referred to as the "National Medical Insurance Catalog") issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, zorifertinib tablets (trade name: Yinuoxin), a next-generation TRK inhibitor independently developed by InnoCare Pharma Limited (hereinafter referred to as the "Company"), has been included in the new version of the National Medical Insurance Catalog for the treatment of adult and adolescent patients aged 12 and above with solid tumors harboring NTRK fusion genes. The new version of the National Medical Insurance Catalog will officially take effect on January 1, 2027.